These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 35598213)

  • 1. [Use of bone pate and bioactive glass granules for mastoid obliteration in cholesteatoma surgery].
    Gerlinger I; Szabó É; Szanyi I; Rostás T; Pap I; Révész P; Kopjár E
    Orv Hetil; 2022 May; 163(21):838-845. PubMed ID: 35598213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Obliteration of mastoid cavities: 30 years of experience with recommendations for surgical strategy].
    Schimanski G; Schimanski E
    HNO; 2015 Aug; 63(8):538-45. PubMed ID: 26219522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mastoid obliteration with hydroxyapatite vs. bone pâté in mastoidectomy surgery performed on patients with cholesteatoma and chronic suppurative otitis media: a retrospective analysis.
    Lindeboom JJ; van Kempen PMW; Buwalda J; Westerlaken BO; van Zuijlen DA; Bom SJH; van der Beek FB
    Eur Arch Otorhinolaryngol; 2023 Apr; 280(4):1703-1711. PubMed ID: 36173443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single flap with three pedicles, bone paté and split-thickness skin graft for immediate mastoid obliteration after canal wall down mastoidectomy.
    Mokbel KM; Khafagy YW
    Eur Arch Otorhinolaryngol; 2012 Sep; 269(9):2037-41. PubMed ID: 22127570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A retrospective analysis of hearing after cholesteatoma surgery: the bony obliteration tympanoplasty versus canal wall up and canal wall down without mastoid obliteration.
    van der Toom HFE; van der Schroeff MP; Metselaar M; van Linge A; Vroegop JL; Pauw RJ
    Eur Arch Otorhinolaryngol; 2022 Nov; 279(11):5181-5189. PubMed ID: 35399107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioactive glass S53P4 in mastoid obliteration surgery for chronic otitis media and cerebrospinal fluid leakage.
    Sarin J; Grénman R; Aitasalo K; Pulkkinen J
    Ann Otol Rhinol Laryngol; 2012 Sep; 121(9):563-9. PubMed ID: 23012893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mastoid obliteration with S53P4 bioactive glass after canal wall down mastoidectomy: Preliminary results.
    Król B; Cywka KB; Skarżyńska MB; Skarżyński PH
    Am J Otolaryngol; 2021; 42(2):102895. PubMed ID: 33429176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term follow-up results of canal wall down tympanoplasty with mastoid obliteration using the bone pate plate for canal wall reconstruction in cholesteatoma surgery.
    Yamamoto Y; Takahashi K; Morita Y; Ohshima S; Takahashi S
    Otol Neurotol; 2014 Jul; 35(6):961-5. PubMed ID: 24853244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tolerance and safety of 45S5 bioactive glass used in obliteration procedures during middle ear surgery: Preliminary results.
    Al Tamami N; Bawazeer N; Fieux M; Zaouche S; Tringali S
    Am J Otolaryngol; 2020; 41(6):102542. PubMed ID: 32620365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mastoid Obliteration Using Autologous Bone Dust Following Canal Wall Down Mastoidectomy.
    Sioshansi PC; Alyono JC; Blevins NH
    Otol Neurotol; 2021 Jan; 42(1):68-75. PubMed ID: 32976343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioactive glass granules for mastoid and epitympanic surgical obliteration: CT and MRI appearance.
    Bernardeschi D; Law-Ye B; Bielle F; Hochet B; Sterkers O; Dormont D; Pyatigorskaya N
    Eur Radiol; 2019 Oct; 29(10):5617-5626. PubMed ID: 30888487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A technique for concurrent procedure of mastoid obliteration and meatoplasty after canal wall down mastoidectomy.
    Kim CW; Oh JI; Choi KY; Park SM; Park MI
    Auris Nasus Larynx; 2012 Dec; 39(6):557-61. PubMed ID: 22321811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mastoid obliteration: autogenous cranial bone pAte reconstruction.
    Roberson JB; Mason TP; Stidham KR
    Otol Neurotol; 2003 Mar; 24(2):132-40. PubMed ID: 12621322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Canal wall up surgery with mastoid and epitympanic obliteration in acquired cholesteatoma.
    Hellingman CA; Geerse S; de Wolf MJF; Ebbens FA; van Spronsen E
    Laryngoscope; 2019 Apr; 129(4):981-985. PubMed ID: 30408197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cochlear implantation after canal wall down mastoidectomy - Outcomes after partial mastoid obliteration.
    Balk M; Schwarz D; Wolber P; Anagiotos A; Gostian AO
    Auris Nasus Larynx; 2019 Aug; 46(4):487-492. PubMed ID: 30442436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bioactive glass S53P4 in the filling of cavities in the mastoid cell area in surgery for chronic otitis media.
    Stoor P; Pulkkinen J; Grénman R
    Ann Otol Rhinol Laryngol; 2010 Jun; 119(6):377-82. PubMed ID: 20583735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bioactive glass obliteration of the mastoid significantly improves surgical outcome in non-cholesteatomatous chronic otitis media patients.
    Vos J; de Vey Mestdagh P; Colnot D; Borggreven P; Orelio C; Quak J
    Eur Arch Otorhinolaryngol; 2017 Dec; 274(12):4121-4126. PubMed ID: 28956143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-Stage Mastoid Obliteration in Cholesteatoma Surgery and Recurrent and Residual Disease Rates: A Systematic Review.
    van der Toom HFE; van der Schroeff MP; Pauw RJ
    JAMA Otolaryngol Head Neck Surg; 2018 May; 144(5):440-446. PubMed ID: 29543959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mastoid Obliteration Using S53P4 Bioactive Glass in Cholesteatoma Surgery: A 10-Year Single-Center Experience in 173 Adult Patients with Long-Term Magnetic Resonance Imaging Controlled Follow-up.
    Kroon VJ; Mes SW; Borggreven PA; van de Langenberg R; Colnot DR; Quak JJ
    Otol Neurotol; 2022 Dec; 43(10):1181-1188. PubMed ID: 36099589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preliminary experience with beta-tricalcium phosphate for use in mastoid cavity obliteration after mastoidectomy.
    Minoda R; Hayashida M; Masuda M; Yumoto E
    Otol Neurotol; 2007 Dec; 28(8):1018-21. PubMed ID: 17898672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.